Lawsuits allege the Bard PowerPort's catheter tubing was defectively designed — prone to fracture, migration, and material degradation inside the body, leading to infections, blood clots, and emergency removal surgeries.
The Bard PowerPort is an implantable port catheter used to deliver chemotherapy, medications, and fluids directly into the bloodstream — most often in cancer patients. Lawsuits allege the polyurethane catheter material (ChronoFlex) degrades and fractures inside the body.
Plaintiffs allege fractured or degraded catheter segments can migrate through the vascular system, cause bloodstream infections and sepsis, produce blood clots and cardiac injuries, and require emergency removal surgery. Claims allege the manufacturer knew of high failure rates from internal testing and adverse-event reports but did not adequately warn physicians or patients.
Federal claims are consolidated in a multidistrict litigation in the District of Arizona (MDL 3081), where thousands of cases are pending and bellwether trial selection is underway.
MDL 3081 in the District of Arizona is active with thousands of pending cases. Bellwether trial selection is underway — an early-stage signal phase, with no global settlement announced.
Qualification criteria change as litigation develops. The only way to know whether your experience may fit the current criteria is a review.
The Bard PowerPort campaign is pre-selected below. Tell us what happened — a specialist will review whether your information may fit the current criteria.
You are reviewing: Bard PowerPort Claims. Complete the form — a case specialist may follow up if your information appears to fit.
Attorney advertising. The Torts Attorney provides legal marketing and case-acquisition services and is not a law firm. Submitting this form does not create an attorney-client relationship and does not guarantee review, acceptance, or any outcome. Prior results do not guarantee similar outcomes.